ES2173082T3 - Vectores retrovirales que contienen sitios de entrada del ribosoma internos. - Google Patents

Vectores retrovirales que contienen sitios de entrada del ribosoma internos.

Info

Publication number
ES2173082T3
ES2173082T3 ES92917724T ES92917724T ES2173082T3 ES 2173082 T3 ES2173082 T3 ES 2173082T3 ES 92917724 T ES92917724 T ES 92917724T ES 92917724 T ES92917724 T ES 92917724T ES 2173082 T3 ES2173082 T3 ES 2173082T3
Authority
ES
Spain
Prior art keywords
ribosome entry
internal ribosome
entry sites
vectors containing
retroviral vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917724T
Other languages
English (en)
Inventor
W French Anderson
Richard A Morgan
Larry Couture
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24981978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2173082(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2173082T3 publication Critical patent/ES2173082T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Traffic Control Systems (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA PRODUCCION DE UN VECTOR RETROVIRAL, QUE ES CAPAZ DE EXPRESION DE SUCESOS DE TRASLACION DE PROTEINAS MULTIPLES DESDE UNA MRNA POLICISTRONICA UNICA, USANDO SITIOS DE ENTRADA DE RIBOSOMA INTERNOS, EN VEZ DE UN ACTIVADOR INTERNO.
ES92917724T 1991-08-07 1992-08-06 Vectores retrovirales que contienen sitios de entrada del ribosoma internos. Expired - Lifetime ES2173082T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74174091A 1991-08-07 1991-08-07

Publications (1)

Publication Number Publication Date
ES2173082T3 true ES2173082T3 (es) 2002-10-16

Family

ID=24981978

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917724T Expired - Lifetime ES2173082T3 (es) 1991-08-07 1992-08-06 Vectores retrovirales que contienen sitios de entrada del ribosoma internos.

Country Status (8)

Country Link
EP (1) EP0598029B1 (es)
JP (1) JP3378962B2 (es)
AT (1) ATE213779T1 (es)
CA (1) CA2114416C (es)
DE (1) DE69232438T2 (es)
DK (1) DK0598029T3 (es)
ES (1) ES2173082T3 (es)
WO (1) WO1993003143A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5589582A (en) * 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
BE1006437A3 (fr) * 1992-12-10 1994-08-30 Company S A Z Sequence nucleotidique destinee au traitement du cancer et des infections.
EP0706319A4 (en) * 1993-01-20 1998-04-22 Biotransplant Inc RETROVIRAL VECTORS WITH THE ABILITY TO EXPRESS MULTIMERAL PROTEINS FROM MULTIPLE TRANSLATION INITIATION LOCATIONS
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
GB9320548D0 (en) * 1993-10-06 1993-11-24 Sandoz Ltd Improvements in or relating to organic compounds
GB2284210B (en) * 1993-11-26 1997-11-12 British Tech Group Translational enhancer DNA from a kinesin gene
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AU780164B2 (en) * 1994-09-13 2005-03-03 Transgene S.A. Novel implant and novel vector for the treatment of acquired diseases
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
WO1996038553A1 (en) * 1995-06-02 1996-12-05 M&E Biotech A/S A method for identification of biologically active peptides and nucleic acids
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
CA2234931C (en) * 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
DK0877752T3 (da) 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
FR2751345B1 (fr) * 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
FR2762615B1 (fr) * 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
EP0938904A1 (en) * 1998-02-09 1999-09-01 Leuven Research & Development vzw Mammalian cell transduction for use in gene therapy
WO1998053063A2 (en) * 1997-05-16 1998-11-26 Leuven Research & Development Vzw Mammalian cell transduction for use in gene therapy
FI110323B (fi) 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
EP2386646B1 (en) 1998-10-01 2016-12-21 University Of Southern California Gene delivery system and methods of use
EP1173597A1 (en) * 1999-04-29 2002-01-23 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US6677500B2 (en) 2000-08-15 2004-01-13 Board Of Trustees Of The University Of Illinois Ungulates expressing exogenous IGF-I in their milk
GB0024550D0 (es) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP1217071B1 (en) 2000-12-22 2010-04-28 Institut National De La Recherche Agronomique Position-independent and tissue specific expression of a transgene in milk of transgenic animals
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
MX2008000985A (es) 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
WO2008066658A2 (en) 2006-11-03 2008-06-05 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2013078433A1 (en) 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
US9657310B2 (en) 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426744A1 (en) * 1988-07-29 1991-05-15 Zymogenetics, Inc. High efficiency translation of polycistronic messages in eucaryotic cells

Also Published As

Publication number Publication date
ATE213779T1 (de) 2002-03-15
WO1993003143A1 (en) 1993-02-18
DE69232438D1 (de) 2002-04-04
CA2114416A1 (en) 1993-02-18
JP3378962B2 (ja) 2003-02-17
DK0598029T3 (da) 2002-05-27
JPH06509713A (ja) 1994-11-02
EP0598029A4 (en) 1996-04-17
EP0598029B1 (en) 2002-02-27
CA2114416C (en) 1998-07-07
DE69232438T2 (de) 2002-10-10
EP0598029A1 (en) 1994-05-25

Similar Documents

Publication Publication Date Title
ES2173082T3 (es) Vectores retrovirales que contienen sitios de entrada del ribosoma internos.
ES2128457T5 (es) Metalocenos con puente de sililo y su utilizacion.
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
GR3014924T3 (en) Mammalian expression of the bmp-2 family.
ATE106401T1 (de) Benzodiazepin-analoge.
ATE193839T1 (de) Reinigung von proteinen
ES2023976B3 (es) Procedimiento para el enriquecimiento de helio.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
ES2081804T3 (es) Peptidos que se corresponden con el dominio de fijacion al factor viii del factor de von willebrand.
DK0852587T3 (da) Syntetiske peptider der inhiberer IL-6-aktivitet
DK0500800T3 (da) Antohæmostatiske Faktor VII-peptider
ES2058518T3 (es) 2-amino-1,2,3,4-tetrahidronaftalenos sustituidos en el anillo.
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
ES2012524A6 (es) Procedimiento para la produccion de colorantes complejos de cromo 1:2.
ATE165369T1 (de) Antikoagulierende peptide
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
ES8302632A1 (es) Un procedimiento para la preparacion de derivados de 9-carbamoil-9-aminoalquilfluoreno.
ATE177432T1 (de) Antikoagulierende peptide
GR3021660T3 (en) Anticoagulant peptides
IT8722485A0 (it) Preparazione di composti epossidici a configurazione cis e trans apartire da miscele degli stereoisomeri olefinici corrispondenti.
EP0295350A3 (en) Use of n-û2-(diethylamino)ethyl¨-2-methoxy-4-û(1-h 4,5-dihydro-2-imidazolyl)amino¨-5-chlorobenzamide as an anxiolytic and antipsychotic agent
ES8801647A1 (es) Un procedimiento para la preparacion de piridazinilimidazolidinonas
FI941394A0 (fi) Peptidejä,jotka kykenevät säätelemään akrosomireaktiota
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 598029

Country of ref document: ES